Moxifloxacin Hydrochloride-Loaded Eudragit® RL 100 and Kollidon® SR Based Nanoparticles: Formulation, In vitro Characterization and Cytotoxicity.

Background: Considering the low ocular bioavailability of conventional formulations used for ocular bacterial infection treatment, there is a need to design efficient novel drug delivery systems that may enhance precorneal retention time and corneal permeability.

Aim And Objective: The current research focuses on developing nanosized and non-toxic Eudragit® RL 100 and Kollidon® SR nanoparticles loaded with moxifloxacin hydrochloride (MOX) for its prolonged release to be promising for effective ocular delivery.

Methods: In this study, MOX incorporation was carried out by spray drying method aiming ocular delivery.

Preparation and in vitro evaluation of vaginal formulations including siRNA and paclitaxel-loaded SLNs for cervical cancer.

Cervical cancer is one of the most life threatening types of cancer among women and is generally resistant to chemotherapy. The objective of this study was to prepare a vaginal suppository containing a chemotherapeutic agent and a genetic material that can be applied locally for cervical cancer. Paclitaxel was selected as the chemotherapeutic agent and siRNA which inhibits BCL-2 oncogene was selected as the genetic material.

In vitro/in vivo evaluation of gamma-aminobutyric acid-loadedN,N-dimethylacrylamide-based pegylated polymeric nanoparticles for brain delivery to treat epilepsy.

Objectives of this study were the delivery of gamma aminobutyric acid (GABA) into the brain by means of developing brain targeted, nanosized, non-toxic and biocompatible polymeric nanoparticles, and investigating their effectiveness in epilepsy. For this purpose, GABA conjugated N,N-dimethylacrylamide-based pegylated nanoparticles were designed and characterised for particle size, zeta potential, pH, morphology, DSC, XRD, FTIR, GABA quantification and in vitro release. Formulations showed smaller particle size, cationic zeta potential characteristic, possible GABA polymeric matrix interaction and prolonged release pattern.

Gamma-aminobutyric acid loaded halloysite nanotubes and in vitro-in vivo evaluation for brain delivery.

Gamma-aminobutyric acid (GABA) is a key neurotransmitter where it usually inhibits impulse transmission. GABA release blockage or postsynaptic reaction were determined to provoke epileptic convulsions. The aim of the present study was the development of brain-targeted, nanosized, nontoxic, biocompatible, highly specific formulations.

Chitosan nanoparticles for ocular delivery of cyclosporine A.

In the present study, cyclosporine A (CsA) was successfully incorporated into cationic chitosan nanoparticles by spray-drying method aiming ocular application. Physicochemical characterisation of particles was performed in detail. Among the particles prepared using three types of chitosan with different molecular weights, particles containing chitosan with medium molecular weight was selected for in vivo studies.

Ocular application of chitosan.

Introduction: A major problem in ocular therapeutics with classical formulations is the maintenance of an effective drug concentration at the site of action for a long period of time. Enhancement of ocular bioavailability with increased dose penetration and longer retention time at desired sites can be achieved by recent formulations. Chitosan stands out with its unique structural advantageous characteristics for different types of formulations like in situ gelling systems, micro- and nanoparticles, inserts, etc.

Polymeric cyclosporine-A nanoparticles for ocular application.

In the present study, cyclosporine A (CsA) was incorporated successfully into cationic Eudragit RS 100 nanoparticles (EPNs) aiming ocular application. Physicochemical characterization of the EPNs prepared was performed during the storage period of 6 months. Following in vitro release tests, sheep were used in in vivo studies where 100 microL of formulation was applied to both eyes (n = 6) under veterinarian supervision.

Cyclosporine-A incorporated cationic solid lipid nanoparticles for ocular delivery.

In the present study, Cyclosporine A (CsA) was successfully incorporated into cationic solid lipid nanoparticles (SLN) for ocular application. Physicochemical characterizations of SLNs were analysed in detail during the storage period of 6 months. Due to the better characteristics like smaller particle size (248.

Formulation and in-vivo evaluation of a cosmetic multiple emulsion containing vitamin C and wheat protein.

The purpose of the study was to see the effect of two antiaging agents in one stable multiple emulsion prepared using natural oil. Vitamin C, which is a very unstable ingredient and is decomposed in the presence of oxygen, active as an antioxidant, was entrapped in the inner aqueous phase of w/o/w multiple emulsion. In this way, slow release can be expected and the effect of vitamin C can be increased since it is protected from the external environment by entrapping it in the internal phase.

Preparation of prolonged release clarithromycin microparticles for oral use and their in vitro evaluation.

Prolonged release microparticles of clarithromycin (CL) were prepared using Eudragit RL 100 and RS 100 by spray-drying and casting-drying techniques. For the characterization of those microparticles, preparation yield, particle size distribution, X-ray diffraction, thermal behavior, active agent content and in vitro dissolution from the microparticles were performed. HPLC was used for the assay of clarithromycin and the assay method was validated.

Preparation and in vitro evaluation of pyridostigmine bromide microparticles.

Pyridostigmine bromide (PB) is an anticholinesterase agent whose aqueous solubility is high and which has a short elimination half-life. Its dosage rate in the treatment of myastenia gravis is frequent due to the short half-life and it exhibits side effects. Microparticles designed to deliver a pharmaceutical active ingredient efficiently at the minimum dose and also to enhance stability, reduce side effects and modify drug release were prepared in this study using an acrylic polymer (Eudragit) as the vehicle by the spray-drying technique.